Quah Qin Xian N, Alnahrawy A, Akshikar R, et al. - Since there is no universal consensus on second-line agents for the treatment of moderate/severe to sight-threatening thyroid eye disease (TED) to maintain remission after first-line intravenous methylprednisolone, researchers tested the safety and effectiveness of mycophenolate mofetil (MMF) in TED patients in a real-world setting and over a longer period than previous randomized controlled trials. The sample consisted of TED patients with active moderate/severe to sight-threatening TED seen over a 4-year period. This research involved 20 patients out of a total of 23. According to this retrospective cohort study, MMF found to be an effective and safe second-line immunosuppressive agent. More research into optimal dosing regimens and treatment duration will be beneficial.